Samantha Lefland
Lawyers
Advises on IP and technology matters, including strategic commercial and licensing arrangements, mergers, acquisitions and other corporate transactions.
Samantha advises clients on a wide range of IP and technology-related corporate and commercial transactions, including licensing and collaboration agreements, supply and distribution agreements and other strategic commercial agreements. She also advises on the IP and technology-related aspects of M&A transactions, joint ventures, financings, restructurings and capital markets offerings.
Experience
Recent Work
- Spirit Airlines prearranged chapter 11 filing
- GSK strategic alliance with Vesalius Therapeutics
- GSK collaboration with Flagship Pioneering
- AC Immune exclusive option and license agreement with Takeda Pharmaceuticals
- Fiserv $2 billion notes offering
- Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
- GSK exclusive license agreement for HS-20093 with Hansoh Pharma
- GSK exclusive license agreement for HS-20089 with Hansoh Pharma
- GSK collaboration extension and new data licensing agreement with 23andMe
- Fiserv $2 billion notes offering
- BMS $35 million investment in Immatics
- Centogene strategic collaboration with Lifera
- Fiserv €800 million notes offering
- GSK exclusive licensing agreement with Scynexis
- Cellular Biomedicine Group CAR-T collaboration and license agreement with Janssen
- Fiserv $1.8 billion notes offering
Insights
Education
J.D., Stanford Law School
- Executive Editor, Stanford Law Review
B.S., Policy Analysis and Management, Cornell University
Qualifications and admissions
- State of New York